The effect of intravesical cocktail therapy combined with low-dose amitriptyline on primary bladder pain syndrome.
Amitriptyline
Bladder pain syndrome
Emotional status
Interstitial cystitis
Intravesical treatment
Journal
International urogynecology journal
ISSN: 1433-3023
Titre abrégé: Int Urogynecol J
Pays: England
ID NLM: 101567041
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
28
09
2021
accepted:
30
10
2021
pubmed:
4
1
2022
medline:
24
5
2022
entrez:
3
1
2022
Statut:
ppublish
Résumé
We compared the effectiveness of intravesical combination treatment and intravesical treatment plus low-dose amitriptyline in patients with primary bladder pain syndrome (PBPS). A total of 53 patients were included in the study. Demographic data, voiding frequency, nocturia, visual analog scale (VAS) scores, validated O'Leary-Sant IC Symptom Index (ICSI), and IC Problem Index (ICPI) scores and scores on the Short Form-36 (SF-36) questionnaire were collected from the patients at the beginning of the treatment, and at the 6th week and 6th month of the treatment. The patients were divided into two groups. Group 1 received intravesical treatment for 6 weeks. Group 2 received intravesical treatment plus amitriptyline at a dosage of 10 mg/day. The frequencies of voiding and VAS scores were significantly improved in groups 1 and 2 at the 6th week compared with pretreatment (in group 1 p < 0.001, p < 0.001, and in group 2 p < 0.001, p < 0.001 respectively). The median ICSI and ICPI scores also significantly decreased in groups 1 and 2 (in group 1 p < 0.001, p < 0.001, and in group 2 p < 0.001, p < 0.001 respectively). Scores on the dimensions of the SF-36 questionnaire were significantly improved in both groups. There was no significant change in terms of VAS, nocturia, ICSI or ICPI scores when comparing the 6th week and 6th month results in groups 1 and 2 (all p > 0.05). Only role functioning/emotional achieved a significant improvement in group 2 (p = 0.007). Intravesical combination therapies are effective in PBPS treatment. Adding low-dose amitriptyline to intravesical therapy in patients with PBPS improves emotional status.
Identifiants
pubmed: 34977954
doi: 10.1007/s00192-021-05043-y
pii: 10.1007/s00192-021-05043-y
doi:
Substances chimiques
Amitriptyline
1806D8D52K
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1225-1230Informations de copyright
© 2021. The International Urogynecological Association.
Références
Esteban M, Adot JM, Arlandis S, Peri L, Prieto L, Salinas J; Working group for recommendations on the diagnosis and management of bladder pain syndrome. Recommendations for the diagnosis and management of bladder pain syndrome. Spanish Urological Association consensus document. Actas Urol Esp. 2015;39:465–72.
doi: 10.1016/j.acuro.2015.01.006
Homma Y. Interstitial cystitis, bladder pain syndrome, hypersensitive bladder, and interstitial cystitis/bladder pain syndrome—clarification of definitions and relationships. Int J Urol. 2019;26(Suppl 1):20–4.
doi: 10.1111/iju.13970
Birder LA. Urinary bladder, cystitis and nerve/urothelial interactions. Auton Neurosci. 2014;182:89–94.
doi: 10.1016/j.autneu.2013.12.005
Cvach K, Rosamilia A. Review of intravesical therapies for bladder pain syndrome/interstitial cystitis. Transl Androl Urol. 2015;4:629–37.
pubmed: 26816864
pmcid: 4708535
Vasudevan V, Moldwin R. Addressing quality of life in the patient with interstitial cystitis/bladder pain syndrome. Asian J Urol. 2017;4:50–4.
doi: 10.1016/j.ajur.2016.08.014
Lins L, Carvalho FM. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med. 2016;4:2050312116671725.
doi: 10.1177/2050312116671725
Keane J, Young N, Goh J, Atherton M, Yin J, Moore K, et al. A comparison of two intravesical bladder instillations for interstitial cystitis/bladder pain syndrome. Eur J Obstet Gynecol Reprod Biol. 2021;256:230–4.
doi: 10.1016/j.ejogrb.2020.10.060
Nickel JC, Shoskes D, Irvine-Bird K. Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome: a key to classification and potentially improved management. J Urol. 2009;182:155–60.
doi: 10.1016/j.juro.2009.02.122
Naliboff BD, Stephens AJ, Lai HH, Griffith JW, Clemens JQ, Lutgendorf S, et al. Clinical and psychosocial predictors of urological chronic pelvic pain symptom change in 1 year: a prospective study from the MAPP research network. J Urol. 2017;198:848–57.
doi: 10.1016/j.juro.2017.05.065
Colaco M, Evans R. Current guidelines in the management of interstitial cystitis. Transl Androl Urol. 2015;4:677–83.
pubmed: 26816869
pmcid: 4708542
Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185:2162–70.
doi: 10.1016/j.juro.2011.03.064
Parsons CL, Zupkas P, Proctor J, Koziol J, Franklin A, Giesing D, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med. 2012;9:207–12.
doi: 10.1111/j.1743-6109.2011.02542.x
Parkin J, Shea C, Sant GR. Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis—a practical approach. Urology. 1997;49:105–7.
doi: 10.1016/S0090-4295(97)00181-7
Nickel JC, Jain P, Shore N, Anderson J, Giesing D, Lee H et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012;4(143):ra100.
doi: 10.1126/scitranslmed.3003804
Berk M, Williams LJ, Jacka FN, O’Neil A, Pasco JA, Moylan S, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200.
doi: 10.1186/1741-7015-11-200
Suskind AM, Berry SH, Suttorp MJ, Elliott MN, Hays RD, Ewing BA, et al. Health-related quality of life in patients with interstitial cystitis/bladder pain syndrome and frequently associated comorbidities. Qual Life Res. 2013;22:1537–41.
doi: 10.1007/s11136-012-0285-5
Romão AP, Gorayeb R, Romão GS, Poli-Neto OB, dos Reis FJ, Rosa-e-Silva JC, et al. High levels of anxiety and depression have a negative effect on quality of life of women with chronic pelvic pain. Int J Clin Pract. 2009;63:707–11.
doi: 10.1111/j.1742-1241.2009.02034.x
Quaghebeur J, Wyndaele JJ. Prevalence of lower urinary tract symptoms and level of quality of life in men and women with chronic pelvic pain. Scand J Urol. 2015;49:242–9.
doi: 10.3109/21681805.2014.984325
Michael YL, Kawachi I, Stampfer MJ, Colditz GA, Curhan GC. Quality of life among women with interstitial cystitis. J Urol. 2000;164:423–7.
doi: 10.1016/S0022-5347(05)67376-4
Welk BK, Teichman JM. Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin. Urology. 2008;71:67–70.
doi: 10.1016/j.urology.2007.09.067
Daniels AM, Schulte AR, Herndon CM. Interstitial cystitis: an update on the disease process and treatment. J Pain Palliat Care Pharmacother. 2018;32:49–58.
doi: 10.1080/15360288.2018.1476433
Van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004;172:533–6.
doi: 10.1097/01.ju.0000132388.54703.4d
Foster HE Jr, Hanno PM, Nickel JC, Payne CK, Mayer RD, Burks DA, et al. Interstitial cystitis collaborative research network. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183:1853–8.
doi: 10.1016/j.juro.2009.12.106
Yeh HL, Jhang JF, Kuo YC, Kuo HC. Long-term outcome and symptom improvement in patients with interstitial cystitis/bladder pain syndrome with or without regular follow-up and treatment. Neurourol Urodyn. 2019;38:1985–93.
doi: 10.1002/nau.24104